drugset / Trial / NCT01466062
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
Non-randomizedSingle-groupOpen-labelPrevention
Summary
To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.
Timeline
- Start
- 2011-08
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palivizumab | Monoclonal antibody | 15 mg/kg | Intramuscular |